Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

Abstract excerpt

The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication after osimertinib treatment a quandary. Dacomitinib has been reported to have potential impact on patients acquiring rare compound mutations after osimertinib...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Lung Cancer Treatments and Mutations
• Share to Pancreatic and Hepatic Oncology Research